Do you want to read an article? Please log in or register.
Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre
United European Gastroenterol J.
Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A
doi: 10.1177/2050640620929133.
Inflammatory Bowel Disease
Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases
Inflamm Bowel Dis.
Attauabi M, Zhao M, Bendtsen F, Burisch J
doi: 10.1093/ibd/izaa167.
Inflammatory Bowel Disease
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease
United European Gastroenterol J.
Guidi L, Pugliese D, Tonucci TP, Bertani L, Costa F, Privitera G, Tolusso B, Di Mario C, Albano E, Tapete G, Gremese E, Papa A, Gasbarrini A, Rapaccini GL, Armuzzi A
doi: 10.1177/2050640619873784.
Inflammatory Bowel Disease
A product review of vedolizumab in inflammatory bowel disease
Hum Vaccin Immunother.
Battat R, Dulai PS, Jairath V, Vande Casteele N
doi: 10.1080/21645515.
Inflammatory Bowel Disease
Causes of Treatment Failure In Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study
J Pediatr Gastroenterol Nutr.
Naviglio S, Lacorte D, Lucafò M, Cifù A, Favretto D, Cuzzoni E, Silvestri T, Pozzi Mucelli M, Radillo O, Decorti G, Fabris M, Bramuzzo M, Taddio A, Stocco G, Alvisi P, Ventura A, Martelossi S
doi: 10.1097/MPG.
Inflammatory Bowel Disease
Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease
United European Gastroenterol J
Grišić AM, Dorn-Rasmussen M, Ungar B, Brynskov J, Ilvemark JFKF, Bolstad N, Warren DJ, Ainsworth MA, Huisinga W, Ben-Horin S, Kloft C, Steenholdt C
doi: 10.1177/2050640620964619
Inflammatory Bowel Disease
Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease
Inflamm Bowel Dis.
Bauman LE, Xiong Y, Mizuno T, Minar P, Fukuda T, Dong M, Rosen MJ, Vinks AA
doi: 10.1093/ibd/izz143.
Inflammatory Bowel Disease
Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel Disease
Inflamm Bowel Dis.
Neto MBB, Gregory MH, Ramos GP, Bazerbachi F, Bruining DH, Abu Dayyeh BK, Kushnir VM, Raffals LE, Ciorba MA, Loftus EV, Deepak P
doi: 10.1093/ibd/izz236.
COMMENTED
Inflammatory Bowel Disease
Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort
★ 1
Recommended and commented by
Prof. Dr Stephan Vavricka, Faculty Member
United European Gastroenterol J
Greuter T, Porchet F, Braga-Neto MB, Rossel JB, Biedermann L, Schreiner P, Scharl M, Schoepfer AM, Safroneeva E, Straumann A, Rogler G, Vavricka SR
doi: 10.1177/2050640620954556